Benefit, harm, and capability ledgers
Events
Frequency · stacked by domain
Events over time
- Medicine & Health
Heatmap
Domain by month
Significance
Impact tiers
Base impact
- T1 · 1Useful / Limited
- T2 · 3Notable / Significant
- T3 · 10Major
- T4 · 30Historic
- T5 · 100Civilizational / Catastrophic
Base points before attribution, evidence, realization, durability, and credit share.
MethodologyFrequency
Benefit versus harm counts
Politicians have failed to tackle health care affordability. It’s now voters’ rallying cry
As costs surge, voters are embracing more radical solutions to the crisis.
STAT+: Nonprofit Bon Secours Mercy Health strikes $5.7 billion deal for surgery center chain
The deal would make the Catholic system one of the largest operators of outpatient surgery centers.
STAT+: Rising premiums, a sad Medicaid gathering, and a new fraud crackdown
The cost of health insurance is surging, and CMS presses ahead with a new fraud crackdown.
STAT+: Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
A targeted drug from Incyte, when used in combination with chemotherapy, induced lasting tumor responses in certain patients with pancreatic cancer
AI Breach of Australian Healthcare Website Sparks Regulation Debate - Carolina Political Review
AI Breach of Australian Healthcare Website Sparks Regulation Debate Carolina Political Review
Immorta Bio says AI helped identify SenoMune-0257, a nine-amino-acid senolytic peptide
On 12 October 2026 Immorta Bio announced it had finished planned preclinical studies of SenoMune-0257, a synthetic nine-amino-acid peptide it says AI helped select to stimulate T cells against senescent cells. The company aims for first human evaluation before year-end 2026. No sequence, named model, public data package, or trial site was disclosed.
STAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say
A recent court decision in Indonesia sends an important message to other countries to challenge the pharma industry's use of "patent evergreening," patient advocates say.
STAT+: Momentum is building for a big change to how doctors get paid
Congress is considering linking doctor payment rates to medical inflation under the proposed Patients First Act.
STAT+: Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatments
Medicines for osteoporosis are grabbing the attention of the pharma industry, which has been incentivized by a long-awaited regulatory change.
The latest in the legal saga for youth gender-affirming care in the U.S.
The chilling effect of the Trump administration's dogged offensive against transgender health care has been swift, with dozens of hospitals across the U.S. ending care, even if they haven't been…
CTSpinoPelvic1K: spine, pelvis, ribs and femora in one coordinate frame, annotated for lumbosacral transitional anatomy
arXiv:2609.22760v1 Announce Type: new Abstract: Purpose: A vertebra at the lumbosacral junction is named by counting caudally from C2 on whole-spine imaging, but a lumbar case is planned on lumbar-only imaging (T12 to S1), without C2. Abdominopelvic CT holds that span plus the lowest ribs and pelvis. Where a lumbosacral transitional vertebra (LSTV) alters the count, the local anatomy is ambiguous: four rib-free vertebrae may be an L1 with a lumbar rib or an L5 assimilated to the sacrum, and six may be a sixth lumbar vertebra, a T12 with aplastic ribs, or a lumbarized S1. CTSpinoPelvic1K asks
STAT+: Why an influential GOP health policy expert still backs the Medicaid cuts — and which policy target is next
Why an influential GOP health policy expert still backs $1 trillion in Medicaid cuts — and which policy target is next.
STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
Shares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting.
Scaling Network Medicine with LLMs for Combinatorial Drug Repurposing in ER+ Breast Cancer
Drug repurposing can accelerate therapy discovery for ER+ breast cancer, but combination selection remains difficult. We developed an LLM-driven network medicine framework that extracts drug--target relationships from 595,122 PubMed abstracts, builds a cross-model consensus network, overlays it onto the KEGG estrogen signaling pathway, and enumerates complementary drug pairs. Candidate combinations are ranked by ComboRank, which aggregates pathway coverage, LLM consensus, RAG validation, cross-method agreement, and ClinicalTrials.gov precedent. The framework identified 166 significant pairs at
Novo Nordisk taps Anthropic's Claude to speed drug discovery - Drug Discovery News
Novo Nordisk taps Anthropic's Claude to speed drug discovery Drug Discovery News
Anthropic Quietly Builds Wet Lab, Pushing AI Drug Discovery Ambitions from Simulation into the Physical World - finance.biggo.com
Anthropic Quietly Builds Wet Lab, Pushing AI Drug Discovery Ambitions from Simulation into the Physical World finance.biggo.com
How Anthropic & Novo Will Use Claude AI for Drug Discovery - AI Magazine
How Anthropic & Novo Will Use Claude AI for Drug Discovery AI Magazine
A Four-Stage Decomposition of Word-Problem Solving and Mechanistic Fragility in LLM Math Reasoning
arXiv:2609.17804v1 Announce Type: new Abstract: Large language models solve grade-school math word problems with high accuracy, yet a single irrelevant clause inserted into the problem can collapse it. We reconcile these observations with a mechanistic account. We show that the model's internal computation decomposes into a four-stage sequential pipeline, Schema Abstraction, Operation Planning, Operand Binding, and Computation, each stage producing a distinct intermediate representation in an identifiable band of layers. Using the same scaffold to diagnose distractor-induced failure, we local
Novo and Anthropic Partner to Apply Claude to Drug Discovery - HLTH
Novo and Anthropic Partner to Apply Claude to Drug Discovery HLTH
Anthropic's Drug Discovery Partners: AI Pharmaceutical Orders Set to Double Next Year - 36Kr
Anthropic's Drug Discovery Partners: AI Pharmaceutical Orders Set to Double Next Year 36Kr
Novo taps Anthropic's Claude AI for drug discovery - pharmaphorum
Novo taps Anthropic's Claude AI for drug discovery pharmaphorum
Novo to partner with Anthropic on drug discovery efforts - Yahoo Finance
Novo to partner with Anthropic on drug discovery efforts Yahoo Finance
How a team of AIs discovered a promising lung-cancer drug
How a team of AIs discovered a promising lung-cancer drug
STAT+: GOP aims to change Medicare adviser’s math so it’s more favorable to health insurers
The GOP bill directs MedPAC to study the topic of overpayments to Medicare Advantage plans in a manner that’s more favorable to insurers.
STAT+: Senators highlight the power Chris Klomp wields at confirmation hearings
Chris Klomp has already played a major role in the Trump administration and its Make America Healthy Again agenda.
Novo Nordisk to Collaborate With Anthropic to Help Accelerate Drug Discovery, Development - Yahoo Finance
Novo Nordisk to Collaborate With Anthropic to Help Accelerate Drug Discovery, Development Yahoo Finance
Novo Nordisk Partners With Anthropic on Drug Discovery and Software Development - citybiz
Novo Nordisk Partners With Anthropic on Drug Discovery and Software Development citybiz
Mutational constraints on RSV F and its neutralization by antibodies
Mutational constraints on RSV F and its neutralization by antibodies
Novo and Anthropic will collaborate to advance drug discovery with Claude - PharmaLive
Novo and Anthropic will collaborate to advance drug discovery with Claude PharmaLive
Novo Nordisk Partners With Anthropic to Apply AI to Drug Discovery and Research - Yahoo Finance
Novo Nordisk Partners With Anthropic to Apply AI to Drug Discovery and Research Yahoo Finance
Novo Nordisk partners with Anthropic to turbocharge drug discovery - StreetInsider
Novo Nordisk partners with Anthropic to turbocharge drug discovery StreetInsider
NVO Stock Alert: What to Know as Novo Partners With Anthropic on Drug Discovery - Barchart.com
NVO Stock Alert: What to Know as Novo Partners With Anthropic on Drug Discovery Barchart.com
Novo Nordisk and Anthropic Will Collaborate on Drug Discovery with Claude - CHEManager
Novo Nordisk and Anthropic Will Collaborate on Drug Discovery with Claude CHEManager
Anthropic and Novo Nordisk expand Claude work, including in drug discovery - R&D World
Anthropic and Novo Nordisk expand Claude work, including in drug discovery R&D World
Novo Nordisk, Anthropic partner on AI drug discovery - MobiHealthNews
Novo Nordisk, Anthropic partner on AI drug discovery MobiHealthNews
Novo and Anthropic will collaborate to advance drug discovery with Claude - GlobeNewswire
Novo and Anthropic will collaborate to advance drug discovery with Claude GlobeNewswire
Danish pharma giant Novo to use Anthropic’s Claude to advance AI drug discovery - Euronews.com
Danish pharma giant Novo to use Anthropic’s Claude to advance AI drug discovery Euronews.com
Anthropic and Danish Company behind Ozempic announce AI drug discovery collaboration - Washington Examiner
Anthropic and Danish Company behind Ozempic announce AI drug discovery collaboration Washington Examiner
Novo Nordisk partners with Anthropic to speed up drug discovery - finance.yahoo.com
Novo Nordisk partners with Anthropic to speed up drug discovery finance.yahoo.com
Novo Announces Drug Discovery Collaboration with Anthropic - Pharmaceutical Executive
Novo Announces Drug Discovery Collaboration with Anthropic Pharmaceutical Executive
Novo and Anthropic will collaborate to advance drug discovery with Claude - Yahoo Finance
Novo and Anthropic will collaborate to advance drug discovery with Claude Yahoo Finance
Novo Nordisk is partnering with Anthropic to speed up drug discovery using AI - qz.com
Novo Nordisk is partnering with Anthropic to speed up drug discovery using AI qz.com
Opinion: How my cancer diagnosis changed the way I train physicians
“The tumors, test results, and treatments I present to future physicians? Mine,” writes David Elkowitz, a professor of pathology and laboratory medicine and science education.
Root-Cause Attribution Is a Search Problem: Continual Search for Long-Horizon Agent Failures
arXiv:2609.13463v1 Announce Type: new Abstract: The increasing deployment of AI agents in long-horizon tasks yields massive execution logs. Diagnosing failures within these records is crucial for reliability, as it transforms outcome-level signals into actionable interventions. The sheer scale of the data renders human review impractical, driving the need for automated root-cause attribution (RCA). However, automated RCA methods using LLMs suffer from low diagnostic accuracy, especially as execution traces grow larger. They struggle because relevant information is often sparse, distributed ac
Insight into the mechanism of molecular interactions of the NDM metallo-beta-lactamase and cyclic boronate inhibition by molecular docking and molecular dynamics simulations
The spread and evolution of antimicrobial resistance (AMR) pose significant threats to public health, food safety, and sustainable development. Metallo bea lactamases (MBLs), a class of carbapenemases that hydrolyze carbapenems, often considered last resort antibiotics, are of particular concern and underscore the urgent need to develop effective inhibitors. Recent advancements in bicyclic boronate inhibitors represent significant progress toward this goal. Although the mechanistic basis of NDM1 inhibition by bicyclic boronate inhibitors remains incompletely elucidated, this study systematical
Grounded Adjudication of Variations across Extracted TimeLines (GAVEL): Comparing Clinical Timelines Against Their Case Reports
arXiv:2609.13475v1 Announce Type: new Abstract: Existing pipelines for clinical timeline extraction from case reports are evaluated using an expert reference and are limited by imperfect reference annotations and imprecise event alignment. We developed GAVEL, an LLM judge protocol that compares two timelines with the case report and returns a discrepancy type, verdict, and report passage for each difference. We evaluated the event matcher, reviewed 2,738 findings from GPT5.6sol and DeepSeek V3.2, ranked six LLM extractors and two human annotators, and tested GAVEL guided merging. True match r
Asclepius: An Adaptive Harness for Long-Horizon Clinical Agents
arXiv:2609.13543v1 Announce Type: new Abstract: LLM agents are predominantly benchmarked on short, single-task trajectories, yet real deployments run for hours under contention, surfacing a different class of failures. We use the Clinical Environment Simulator (CES), in which an agent manages an entire emergency-department shift under continuous time and resource pressure, as a testbed: long-horizon execution failures manifest measurably in a single rollout under structured, multi-dimensional grading. On CES, current agents reach the correct diagnosis in most cases yet fail to deliver complet
STAT+: New documents reveal problems with Medicare’s prior-authorization pilot
In this edition of STAT Health Tech: The rushed launch of Medicare's AI prior-authorization pilot, policy hints from FDA, ONC officials, and more.
STAT+: How $500 explains Republican health policy, and the GLP-1 Rx wave
The one health care policy Republicans agree on, and a look at how rural providers are approaching AI.
Reading the Whole Heart: Latent-Attention Masked Autoencoders for Multimodal Cardiac Representation Learning
arXiv:2609.12035v1 Announce Type: new Abstract: Cardiovascular diagnosis rests on integrating complementary modalities, like ECG, echocardiography, chest radiographs, and clinical variables, each capturing distinct but correlated aspects of cardiac physiology. Yet most medical foundation models remain modality-specific, combining modalities only for finetuning or post-training. This discards the cross-modal evidence clinicians naturally integrate and ignores the structure within each modality. We introduce Latent-Attention Masked Autoencoders (LAMAE), a multimodal, structure-aware masked auto
Language Is an Insufficient Substrate for Quantitative Reasoning, and Consequential Domains Need Large Quantitative Models
arXiv:2609.12105v1 Announce Type: new Abstract: The prevailing assumption in applied machine learning is that progress on consequential quantitative decisions such as pricing risk, allocating capital, triaging patients, or containing a network intrusion will follow from progress in large language models (LLMs). A language model is trained on a representation of the world that was produced by human description; description is a lossy encoding of the quantitative record, and the loss is irreversible: no downstream model, at any scale, can recover from a description what the description did not
STAT+: GSK touts lung cancer data from two drugs
Late-stage results for Definium's LSD treatment, AstraZeneca breast cancer drug fails key trial, and more biotech news from The Readout
A structural antibody benchmark for leakage-aware deep-learning evaluation
Deep-learning methods for antibody structure prediction, antibody-antigen interaction modelling and design are advancing rapidly. However, comparisons across studies remain difficult because training and test sets are often constructed independently, and a temporal cutoff alone does not prevent train-test leakage. We present SABLE (Structural Antibody Benchmark for deep-Learning Evaluation), a versioned structural antibody resource that couples a fixed training collection with a leakage-controlled held-out test set for reproducible machine-learning development and evaluation. SABLE combines 16
Daily briefing: Skeleton teeth show evidence of the earliest known habitual drug use
Daily briefing: Skeleton teeth show evidence of the earliest known habitual drug use
FDA authorizes Powerful Medical’s Queen of Hearts EKG heart-attack triage model
In early September 2026 the FDA issued a de novo classification for Powerful Medical’s Queen of Hearts algorithm, which reads electrocardiograms to help triage chest-pain patients, including occlusions that lack classic ST-segment elevation.
Protege DataLab associates faster ambient AI adoption with lower 2026 in-system mortality
A Protege DataLab / a16z chart, recirculated by Hedgeye on 20 September 2026, plots in-system mortality per 100k patients by ambient AI adoption (share of notes referencing AI tools). High- and low-adoption systems tracked together from 2023 through 2025, then the 2026* points diverge to about 1,010 versus 1,620. Error bars are wide, 2026 is incomplete, no named model is identified, and the authors frame related network figures as descriptive rather than causal.
Stein-Erik Soelberg kills his mother and himself after extended GPT-4o use
On 5 August 2025 Stein-Erik Soelberg, 56, killed his mother Suzanne Adams, 83, in Greenwich, Connecticut, and died by suicide. Estates later sued OpenAI and Microsoft, alleging ChatGPT/GPT-4o validated paranoid delusions; OpenAI disputes causation.
Rentosertib, an AI-designed TNIK inhibitor, posts Phase 2a IPF results
Insilico Medicine’s rentosertib (ISM001-055), discovered with generative models, met a Phase 2a safety endpoint in 71 IPF patients; the 60 mg daily arm showed a mean FVC gain of 98.4 ml versus a 20.3 ml decline on placebo.
Sam Nelson dies of an overdose after alleged ChatGPT drug-combination advice
Sam Nelson, 19, died of a drug overdose on 31 May 2025. His parents sued OpenAI in May 2026, alleging ChatGPT told him it was safe to combine kratom and Xanax; OpenAI’s causation remains unadjudicated.
Adam Raine, 16, dies by suicide after months of ChatGPT conversations
Adam Raine died by suicide on 11 April 2025 in California. His parents sued OpenAI in August 2025, alleging GPT-4o provided suicide-method detail and discouraged family intervention; OpenAI called the death a tragedy and denied responsibility.
AMIE outperforms primary-care physicians on a text OSCE study
Google’s AMIE diagnostic-dialogue system beat 20 primary-care physicians on most specialist and patient-actor axes in a randomized text-chat OSCE, posted in 2024 and published in Nature on 9 April 2025.
Gemini-based AI co-scientist proposes liver-fibrosis targets later tested in organoids
Google’s multi-agent AI co-scientist, built on Gemini 2.0, proposed epigenetic targets and drugs for liver fibrosis; Stanford collaborators reported anti-fibrotic activity of vorinostat and BRD4 inhibitors in human hepatic organoids.
Teen dies by suicide after extended Character.AI chatbot use
Sewell Setzer III, 14, died by suicide on 28 February 2024 after months of sexualized and emotionally intense chats with Character.AI bots; his mother sued in October 2024, and the parties later reported a 2026 settlement.
Explainable graph networks identify a new MRSA-active antibiotic class
MIT and Broad researchers used ensembles of graph neural networks over 12 million compounds to find a structural class active against MRSA and VRE in mice, published 20 December 2023 in Nature.
UnitedHealth’s nH Predict algorithm is accused of driving post-acute care denials
A November 2023 STAT investigation and the Lokken class action allege that naviHealth’s nH Predict model was used to cut Medicare Advantage rehab stays; UnitedHealth says the tool is only a guide.
AlphaMissense classifies most possible human missense variants
DeepMind released AlphaMissense and a catalog covering about 71 million human missense variants, classifying 89 percent as likely benign or likely pathogenic, in Science on 19 September 2023.
NEDA disables Tessa after the chatbot gives diet advice to people with eating disorders
On 30 May 2023 the National Eating Disorders Association took down Tessa after users showed it recommending calorie restriction and weekly weight loss, contrary to eating-disorder care.
Deep learning identifies abaucin, a narrow-spectrum Acinetobacter antibiotic
MIT and McMaster researchers trained a neural net on in-vitro growth data and identified abaucin, which killed A. baumannii in culture and a mouse wound model, published 25 May 2023.